About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Houston | 429 Studies

Clinical Trials MelanomaHouston

Melanoma Clinical Trials in Houston

Find 429 clinical trials for melanoma near Houston, Texas. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Houston

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 281-300 of 429 trials

TerminatedParallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I PortionThe goal of the first phase of this clinical research study is to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to…NCT00791271·Houston, Texas TerminatedA Safety Study of SGN-CD47M in Patients With Solid TumorsThis trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur.NCT03957096·Cleveland, Ohio and 4 others TerminatedPhase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesThe purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered…NCT02608268·Baltimore, Maryland and 13 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedStudy of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerThis is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose…NCT03809624·Scottsdale, Arizona and 22 others

TerminatedA FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementFirst-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF…NCT04543188·Duarte, California and 44 others

CompletedFT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint…NCT03841110·San Diego, California and 3 others

CompletedSTAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the BrainThis phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to…NCT01904123·Houston, Texas

CompletedSafety of TKI258 in Advanced/Metastatic Melanoma SubjectsThis study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258.NCT00303251·Louisville, Kentucky and 2 others

UnknownSafety and Efficacy Study of DCVax-Direct in Solid TumorsThe study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component…NCT01882946·Orlando, Florida and 1 other

RecruitingCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionThis study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.NCT05334069·Anchorage, Alaska and 746 others

CompletedInterferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With MelanomaRATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.NCT00002882·Houston, Texas

Active not recruitingDiet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving ImmunotherapyThis is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and…NCT04645680·Houston, Texas

CompletedIpilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaPhase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab.NCT01740297·Tucson, Arizona and 39 others

TerminatedSample Collection From Melanoma PatientsThe goal of this laboratory research study is to collect blood and tumor samples from patients with malignant melanoma.NCT00507325·Houston, Texas

CompletedA Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.NCT00378482·Los Angeles, California and 5 others

CompletedSafety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineIn this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors.NCT03633110·La Jolla, California and 10 others

Active not recruitingGenetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaThis pilot phase I trial studies the side effects and best dose of genetically modified T-cells followed by aldesleukin in treating patients with stage III-IV melanoma.NCT01955460·Houston, Texas

TerminatedStudy of PF-07265807 in Participants With Metastatic Solid Tumors.A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid TumorsNCT04458259·Fayetteville, Arkansas and 32 others

TerminatedStudy of IK-595 in RAS- or RAF-altered Advanced TumorsThis is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary…NCT06270082·Duarte, California and 14 others

CompletedA Study of Intratumoral IMO-2125 in Patients With Refractory Solid TumorsThis is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.NCT03052205·Scottsdale, Arizona and 11 others

PreviousPage 15 of 22Next

Other Conditions in Houston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma